Blume Elizabeth D, Naftel David C, Bastardi Heather J, Duncan Brian W, Kirklin James K, Webber Steven A
Department of Cardiology, Children's Hospital Boston, Boston, MA 02115, USA.
Circulation. 2006 May 16;113(19):2313-9. doi: 10.1161/CIRCULATIONAHA.105.577601.
Current ventricular assist devices (VADs) in the United States are designed primarily for adult use. Data on VADs as a bridge to transplantation in children are limited.
A multi-institutional, prospectively maintained database of outcomes in children after listing for heart transplantation (n=2375) was used to analyze outcomes of VAD patients (n=99, 4%) listed between January 1993 and December 2003. Median age at VAD implantation was 13.3 years (range, 2 days to 17.9 years); diagnoses were cardiomyopathy (78%) and congenital heart disease (22%). Mean duration of support was 57 days (range, 1 to 465 days). Seventy-three percent were supported with a long-term device, with 39% requiring biventricular support. Seventy-seven patients (77%) survived to transplantation, 5 patients were successfully weaned from support and recovered, and 17 patients (17%) died on support. In the recent era (2000 to 2003), successful bridge to transplantation with VAD was achieved in 86% of patients. Peak hazard for death while waiting was the first 2 weeks after VAD placement. Risk factors for death while awaiting a transplant included earlier era of implantation (P=0.05), female gender (P=0.02), and congenital disease diagnosis (P=0.05). There was no difference in 5-year survival after transplantation for patients on VAD at time of transplantation as compared with those not requiring VAD.
VAD support in children successfully bridged 77% of patients to transplantation, with posttransplantation outcomes comparable to those not requiring VAD. These encouraging results emphasize the need to further understand patient selection and to delineate the impact of VAD technology for children.
美国目前的心室辅助装置(VAD)主要设计用于成人。关于VAD作为儿童移植桥梁的数据有限。
使用一个多机构前瞻性维护的儿童心脏移植登记后结局数据库(n = 2375),分析1993年1月至2003年12月期间登记的VAD患者(n = 99,4%)的结局。VAD植入时的中位年龄为13.3岁(范围:2天至17.9岁);诊断为心肌病(78%)和先天性心脏病(22%)。平均支持时间为57天(范围:1至465天)。73%的患者使用长期装置支持,其中39%需要双心室支持。77例患者(77%)存活至移植,5例患者成功撤机并康复,17例患者(17%)在支持过程中死亡。在最近时期(2000年至2003年),86%的患者通过VAD成功过渡到移植。等待期间死亡的高峰风险是VAD放置后的前2周。等待移植期间死亡的风险因素包括植入时间较早(P = 0.05)、女性(P = 0.02)和先天性疾病诊断(P = 0.05)。移植时使用VAD的患者与未使用VAD的患者相比,移植后5年生存率无差异。
儿童VAD支持成功地使77%的患者过渡到移植,移植后结局与未使用VAD的患者相当。这些令人鼓舞的结果强调了进一步了解患者选择以及明确VAD技术对儿童影响的必要性。